2024 MEDICARE PRIOR AUTHORIZATION REQUEST FORM



Nucala - Medicare

Phone: 215-991-4300 Fax back to: 866-371-3239

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.

PLEASE NOTE. Any information (patient, prescriber, drug, labs) left blank, ineglible, or not attached with delay the review process.		
Patient Name:	Prescriber Name:	
Member Number:	Fax: Phone:	
Date of Birth:	Office Contact:	
Line of Business: □ Medicare	NPI: State Lic ID:	
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	
REQUEST FOR EXPEDITED REVIEW: By checking this box and signing below, le life or health of the enrollee or the enrollee's ability to regain maximum functions.	certify that applying the 72 hour standard review timeframe may seriously jeopardize tion.	
Drug Name:		
Strength:		
Directions / SIG:		
Please attach any pertinent medical history including labs and information for this member that may support approval. Please answer the following questions and sign.		
Q1. Is this a renewal request?		
☐ Yes	□ No	
Q2. FOR RENEWALS: Has the prescriber provided confirmation of a positive clinical response?		
☐Yes	□ No	
Q3. Is Nucala being prescribed by a pulmonologist, allergist, immunologist, rheumatologist, hematologist, or otolaryngologist?		
☐Yes	□ No	
Q4. Is the patient 6 years of age or older?		
☐Yes	□ No	
Q5. Does the patient have a diagnosis of severe asthma with an eosinophilic phenotype with absolute blood eosinophil count equal to or greater than 150 microliters (please attach laboratory results)?		

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document

2024 MEDICARE PRIOR AUTHORIZATION REQUEST FORM



Nucala - Medicare

Phone: 215-991-4300 Fax back to: 866-371-3239

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.

Patient Name:	Prescriber Name:
☐ Yes	□ No
Q6. Has the patient tried and had inadequate response, intolerance or contraindication to treatment with an inhaled ICS/LABA (inhaled corticosteroid/long-acting beta-agonist) with or without other controllers, including systemic steroids, antileukotrienes?	
☐ Yes	□ No
Q7. Does the patient have a diagnosis of relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA)? Please attach documentation.	
□ Yes	□ No
Q8. Does the patient have a diagnosis of hypereosinophilic syndrome for greater than or equal to 6 months without an identifiable non-hematologic secondary cause?	
□ Yes	□ No
Q9. Does the patient have a diagnosis of chronic rhinosinusitis with nasal polyps (CRSwNP) with inadequate response to nasal corticosteroids? Please attach documentation.	
☐ Yes	□ No
Q10. Requested Duration:	
☐ 12 Months	☐ Other:
Q11. Additional Information:	
Prescriber Signature	Date
	2024 Medicare Prior Authorization Request

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document